OncoMatch

OncoMatch/Clinical Trials/NCT07470853

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

Is NCT07470853 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including HWK-016, MUCIN-16-targeted ADC and Bevacizumab for proc.

Phase 1RecruitingWhitehawk Therapeutics, Inc.NCT07470853Data as of May 2026

Treatment: HWK-016, MUCIN-16-targeted ADC · Bevacizumab — HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors. The study employs a dose escalation and dose expansion design without a control group. The study consists of 2 parts (Part A: monotherapy and Part B: combination therapy with bevacizumab); each part has 2 phases, Phase 1a (dose escalation) and Phase 1b (dose expansion). Enrollment to Part A (Phase 1a and Phase 1b) will include ovarian and endometrial cancers. Enrollment to Part B (Phase 1a and Phase 1b) will include ovarian cancer only. A subsequent protocol amendment may evaluate additional tumor types.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Endometrial Cancer

Lab requirements

Cardiac function

Significant cardiovascular disease; QTcF ≥ 470 ms

Significant cardiovascular disease; Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University of Arkansas - Winthrop P. Rockefeller Cancer Institute · Little Rock, Arkansas
  • START - Los Angeles · Los Angeles, California
  • SCRI - Florida Cancer Specialists · Sarasota, Florida
  • St. Francis Medical Center (OSF Healthcare) · Peoria, Illinois
  • Karmanos Cancer Center · Detroit, Michigan

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify